• small-logo-tag

  • small-logo-tag

  • small-logo-tag

  • small-logo-tag

  • small-logo-tag

  • small-logo-tag

  • small-logo-tag

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7

2018 News Releases

Webcast ImageWebcast
MIMEDX GROUP INC Shareholder Call (Replay)
Feb 23, 2018 at 10:30 a.m. ET
MIMEDX GROUP INC Shareholder Call
Friday, February 23, 2018 10:30 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014
DateTitle 
Feb 21, 2018MiMedx to Host Conference Call on February 23, 2018 at 10:30 AM Eastern Time
MARIETTA, Ga., Feb. 21, 2018 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), a leading developer and marketer of regenerative and therapeutic biologics, announced today that it will host a live broadcast of the Company's conference call to provide an operational update on Friday, February 23, 2018 at 10:30 a.m. eastern time. A listen-only webcast of the live call will be available at the Company's website at www.mimedx.com.  The webcast replay will be available for 30 days beginning approx... 
Printer Friendly Version
Feb 20, 2018MiMedx Postpones Release of its Fourth Quarter and Fiscal Year 2017 Financial Results
MARIETTA, Ga., Feb. 20, 2018 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), a leading developer and marketer of regenerative and therapeutic biologics, today announced that it will postpone the release of its financial results, as well as the filing of its Form 10-K, for the year ended December 31, 2017. The Audit Committee of MiMedx's Board of Directors has engaged independent legal and accounting advisors to conduct an internal investigation into current and prior-period matters relatin... 
Printer Friendly Version
Jan 25, 2018MiMedx Adds New Materials To Its Website Exposing Misinformation Disseminated Through Short Sellers
MARIETTA, Ga., Jan. 25, 2018 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts and patent-protected processes for multiple sectors of healthcare, announced today that it has posted additional materials on the Company's website that further expose the misinformation disseminated through short sellers. The new materials can be found on the MiMedx we... 
Printer Friendly Version
Jan 18, 2018MiMedx Comments on Magistrate Recommendation in the Company's Lawsuit Against Short Sellers
MARIETTA, Ga., Jan. 18, 2018 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare, today commented on the recommendation from the Magistrate in New York that the claims be dismissed against some of the parties in the Company's lawsuit against various short sellers. In October 2017, MiM... 
Printer Friendly Version
Jan 17, 2018MiMedx Announces the Enrollment of the First Patients in the Phase 3 Clinical Trial of AmnioFix® Injectable for Achilles Tendonitis
MARIETTA, Ga., Jan. 17, 2018 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare, today announced that the first patients have been randomized and enrolled in the Company's Phase 3 Investigational New Drug (IND) clinical trial for MiMedx's micronized amniotic tissue, AmnioFix® Injectable... 
Printer Friendly Version
Jan 16, 2018MiMedx Announces First Patients Have Been Enrolled In The Phase 3 Clinical Trial Of AmnioFix® Injectable In Patients With Recalcitrant Plantar Fasciitis Pain
MARIETTA, Ga., Jan. 16, 2018 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare, today announced the first patients have been randomized and enrolled in the pivotal Phase 3 Investigational New Drug (IND) clinical trial to assess the safety and efficacy of AmnioFix® Injectable in patient... 
Printer Friendly Version
Jan 12, 2018Mimedx To Host Shareholder Call On January 18, 2018 To Update Progress On Multiple Clinical Studies And Status Of Patent Portfolio
MARIETTA, Ga., Jan. 12, 2018 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare, announced that it will host a webcast on Thursday, January 18, 2018 beginning at 10:30 a.m. eastern time. The Company reported that "Pete" Petit, Chairman and CEO; Bill Taylor, President and COO; Chris C... 
Printer Friendly Version
Jan 11, 2018MiMedx Obtains Successful Settlement Of Its Patent Infringement Lawsuit Against Musculoskeletal Transplant Foundation, Medline Industries And Liventa Bioscience, Inc.
MARIETTA, Ga., Jan. 11, 2018 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing proprietary human placental tissue allografts, today announced that it successfully settled the Company's longstanding patent infringement lawsuit against Musculoskeletal Transplant Foundation, Inc. ("MTF"), Medline Industries, Inc. ("Medline") and Liventa Bioscience, Inc. ("Liventa").     In April 2014,... 
Printer Friendly Version
Jan 07, 2018MiMedx Releases Preliminary 2017 Revenue of $324.5 Million representing a 32% increase over 2016
FOURTH QUARTER 2017 PRELIMINARY REVENUE OF $90.9 MILLION SURPASSES UPPER RANGE OF Q4 GUIDANCE BY NEARLY $3 MILLION MARIETTA, Ga., Jan. 7, 2018 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare, today announced preliminary record revenue results for the fourth quarter and full-yea... 
Printer Friendly Version
Jan 05, 2018MiMedx Provides Update On Illegal Short Selling Activities Against The Company
MARIETTA, Ga., Jan. 5, 2018 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing proprietary human placental tissue allografts, today provided answers to certain questions being asked by MiMedx shareholders related to the illegal short selling attacks the Company is experiencing. The Company reminds shareholders that updates are made regularly to the MiMedx website within the "Short S... 
Printer Friendly Version
Jan 02, 2018MiMedx To Present At 36th Annual J.P. Morgan Healthcare Conference
MARIETTA, Ga., Jan. 2, 2018 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare, announced today that it will present at the 36th Annual J.P. Morgan Healthcare Conference.  Parker H. "Pete" Petit, Chairman and CEO, Michael J. Senken, Chief Financial Officer, Christopher M. Cashman, EVP a... 
Printer Friendly Version

Products

CONTACT US

888.543.1917